As China's economic growth declines, some analysts say Beijing may have to spend more on infrastructure, adding to concerns about high debts.China Economyread more
U.S. President Donald Trump said Tuesday that Washington and Beijing have a long way to go on trade, adding that America could place tariffs on an additional $325 billion...Asia Marketsread more
"The charts, as interpreted by Carley Garner, suggest that the upside in the stock market has gotten more limited," Jim Cramer says.Mad Money with Jim Cramerread more
John Paul Stevens, who served on the Supreme Court for nearly 35 years and became its leading liberal, has died.Politicsread more
The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
The WTO ruling recognized that the United States had proved that China used state-owned enterprises to subsidize and distort its economy. But the U.S. must accept Chinese...World Economyread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
Delta is gathering more data from customers than ever in hopes of avoiding customer service problems and increasing customer satisfaction, its CFO says.At Workread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
U.S. cancer drug company Medivation is discussing opening its books to Sanofi after the French pharmaceutical company sweetened its $9.3 billion acquisition offer, people familiar with the matter said on Tuesday.
The talks come after Medivation rejected Sanofi's $52.50 per share cash offer in April, prompting Sanofi to embark on a campaign to convince Medivation shareholders to oust Medivation's board of directors and replace them with its nominees in a so-called written consent process.
Medivation is negotiating the terms of a confidentiality agreement with Sanofi that would allow the two companies to engage in deal negotiations, the people said.
There is no certainty that Medivation will agree to a sale with any party, the people cautioned.
The sources asked not to be identified because the deliberations are confidential. Medivation and Sanofi declined to comment, while Pfizer and Celgene did not immediately respond to requests for comment.
Medivation shares jumped as much as 4.2 percent on the news and were trading up 2.5 percent at $61.62 in afternoon trading in New York.
Sanofi's new offer, whose terms could not be immediately learned, came following conversations with Medivation shareholders. Last month, shareholder advisory firm Glass Lewis & Co recommended that Medivation's shareholders should not support Sanofi's efforts to replace the company's board members.
Sanofi wants Medivation - which sells a successful prostate cancer drug called Xtandi - so Sanofi can expand in the lucrative oncology sector, as it seeks new businesses to compensate for flagging diabetes revenues.
Reuters had reported in May that Medivation had signed confidentiality agreements with some companies, including Pfizer.
Medivation had previously argued that Sanofi's offer had failed to value fairly the prospects for Xtandi, as well as two other products currently in clinical trials - Talazoparib, for the treatment of breast cancer, and Pidilizumab, for the treatment of blood cancers.